Clinical trial
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast…
NCT00244933 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00244933 |
|---|---|
| Title | Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer |
| Official title | Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Dietary Supplement, Drug, Procedure |
| Interventions | genistein, gemcitabine, Tumor biopsy |
| Enrollment | 19 |
| Start date | Feb 1, 2004 |
| Primary completion | Nov 1, 2008 |
| Completion | Oct 1, 2009 |
| First posted | Oct 27, 2005 |
| Last update posted | Jun 22, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: